Showing 7301-7310 of 7612 results for "".
- Valeant, Galderma Revise Agreement Termshttps://practicaldermatology.com/news/20121210-valeant_galderma_revise_agreement_terms/2459661/Valeant Pharmaceuticals International, Inc. reached agreement on terms of a revised North American aesthetics arrangement with Galderma S.A. Under the terms, Galderma will continue to supply Restylane and Perlane to Valeant, under the terms and co
- AD RescueWear Receives NEA Seal of Acceptancehttps://practicaldermatology.com/news/20121204-ad_rescuewear_receives_nea_seal_of_acceptance/2459662/The National Eczema Association Seal of Acceptance was awarded to AD RescueWear for its use by patients with eczema or severe sensitive skin conditions. AD RescueWear manufactures and sells ready-made, wet wrap therapy products for the treatment
- ARTAS System Adopted by Minneapolis Surgeonhttps://practicaldermatology.com/news/20121204-artas_system_adopted_by_minneapolis_surgeon/2459664/Restoration Robotics, Inc. announced the first use of its revolutionary ARTAS System in Minneapolis by Dr. Ron Shapiro of Shapiro Medical Group. The ARTAS System is the first and only FDA-cleared, physician-controlled, computer-assisted technolo
- ZO Skin Health Opens in Pasadenahttps://practicaldermatology.com/news/20121203-zo_skin_health_opens_in_pasadena/2459666/ZO® Skin Health, described as a cutting-edge center that offers the latest in skin transformation and anti-aging technology and treats a wide range of skin conditions including acne, scars, large pores and skin imperfections, opened November
- Merz, Inc. Acquires ONMEL Oral Treatment for Toenail Fungal Infectionshttps://practicaldermatology.com/news/20121128-merz_inc_acquires_onmel_oral_treatment_for_toenail_fungal_infections/2459671/Merz, Inc. completed the acquisition of ONMEL (itraconazole), an azole antifungal indicated for the oral treatment of onychomycosis of the toenail caused by Trichophyton rubrumor T. Mentagrophytes in non-immunocompromised patients. According to the compa
- Physician Income "Disappointing," But Up Slightlyhttps://practicaldermatology.com/news/20121121-physician_income_disappointing_but_up_slightly/2459674/Although most physicians report that their net income is "disappointing," American physicians saw a slight uptick in income in 2012 compared to 2011, a new report shows. Specialists continue to outpace primary care physicians; 40% of the latter make less than $150,000 per year,
- Eccrine Sweat Glands' Role in Wound Healing Revealedhttps://practicaldermatology.com/news/20121121-eccrine_sweat_glands_role_in_wound_healing_revealed/2459675/Human eccrine sweat glands store a reservoir of adult stem cells that may be recruited to aid wound healing, a new report suggests. According to University of Michigan researchers behind the study (Am J Pathol. E-pub), sweat glands appear to play a pivotal role in wound healing. For the study, part
- Picato Approved in European Unionhttps://practicaldermatology.com/news/20121119-picato_approved_in_european_union/2459677/The European Commission has granted marketing authorization for LEO Pharma's Picato (ingenol mebutate) gel for the treatment of actinic keratosis in the European Union (EU). Picato was approved in the US earlier this year.
- Sun Pharmaceutical to Buy DUSA Pharmaceuticalshttps://practicaldermatology.com/news/20121118-sun_pharmaceutical_to_buy_dusa_pharmaceuticals/2459678/Sun Pharmaceutical Industries Ltd. will buy DUSA Pharmaceuticals Inc. for about $215 million in cash, as the India-based company looks to make a foray into the lucrative market for dermatological treatments. The deal has been unanimously approved by the boards of both companies and DUSA's board has
- Xeljanz Approved for Rheumatoid Arthritishttps://practicaldermatology.com/news/20121118-xeljanz_approved_for_rheumatoid_arthritis/2459679/The FDA recently approved Xeljanz (tofacitinib) for the treatment of moderately to severely active rheumatoid arthritis (RA) in adults who have had an inadequate response to, or who are intolerant of, methotrexate. The decision comes ahead of the product's prescription drug user fee goal date of Nov